KQB548 for Solid Tumor Cancers
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called KQB548 for individuals with advanced solid tumors, specifically those with a KRAS G12D mutation. The trial aims to determine if KQB548 can shrink tumors and how the body processes it. It will also establish the safe dosage of the drug. Potential participants have certain types of cancer, such as pancreatic, colorectal, or lung cancer, that have progressed after standard treatments. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.
Will I have to stop taking my current medications?
The trial requires that you do not take certain medications, specifically strong or moderate CYP3A inhibitors or inducers, and proton-pump inhibitors. If you are on these medications, you may need to stop them to participate in the trial.
Is there any evidence suggesting that KQB548 is likely to be safe for humans?
Research has shown that KQB548 is being tested for safety and effectiveness in treating advanced solid tumors with the KRAS G12D mutation. As this trial is in its early stages, the primary goal is to determine a safe dose for humans and understand how the body processes the treatment.
Early studies focus mainly on safety. Although detailed safety information for KQB548 is not yet available, researchers closely monitor any side effects and how well patients tolerate the treatment. Results from this phase will determine if the treatment is safe enough for larger studies.
Even without specific safety data from earlier trials, this stage is crucial for ensuring safety before proceeding to larger studies.12345Why do researchers think this study treatment might be promising?
KQB548 is unique because it targets solid tumor cancers in a way that traditional treatments like chemotherapy and radiation don't. Unlike these standard options that attack both cancerous and healthy cells, KQB548 is designed to specifically target tumor cells, potentially reducing side effects. Researchers are excited about KQB548's novel mechanism of action, as it may offer a more precise and effective approach to treating solid tumors, potentially leading to better patient outcomes.
What evidence suggests that KQB548 might be an effective treatment for solid tumor cancers?
Research shows that KQB548 is being developed to treat cancers with a specific genetic change known as KRAS G12D. This mutation is common in many solid tumors, making them difficult to treat. KQB548 is designed to directly target this change, potentially stopping cancer cell growth. Early studies suggest that treatments focusing on specific genetic changes can shrink tumors and slow disease progression. However, detailed information about its effectiveness in humans remains limited. The current trial primarily evaluates the safety and pharmacokinetics of KQB548 in the Monotherapy Dose Escalation arm.13467
Are You a Good Fit for This Trial?
This trial is for individuals with advanced solid tumors that have a specific genetic change called KRAS G12D mutation. The exact eligibility criteria are not provided, but typically participants must be adults with measurable disease who can take oral medication and have acceptable organ function.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive KQB548 to evaluate safety, tolerability, and efficacy in treating advanced solid malignancies with a KRAS G12D mutation
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- KQB548
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kumquat Biosciences Inc.
Lead Sponsor